The formulation of a candidate drug for first in human (FIH) trials is of great importance – how a pharmaceutical company chooses to approach this challenge can ultimately determine whether or not a drug candidate goes on to win regulatory approval and eventually enter the market. Torkel Gren of Recipharm discusses how in order to even progress to late-stage trials, the formulation of a candidate drug must be carefully selected for FIH trials, as favourable decisions at the earliest opportunity are vital to its success.